Articles

Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

Karel Pavelka MD PhD, Zoltán Szekanecz MD PhD DSc, Nemanja Damjanov MD PhD, Branimir Anić MD PhD, Matija Tomšič MD PhD, Vadim Mazurov MD PhD, Marija Maksimovic MD, Orsolya Nagy MD PhD, Jerzy Świerkot MD PhD, Tzvetanka Petranova MD PhD, Tiina Veldi MD, Asta Baranauskaitė MD PhD, Catalin Codreanu MD PhD, Daina Andersone MD PhD, Roy Fleischmann MD

Article Type

Original Research

Published

This post hoc analysis of SELECT-COMPARE reports, for the first time, the efficacy and safety of upadacitinib 15 mg in combination with methotrexate
(MTX) in patients from the Central and Eastern European region with MTX inadequate response rheumatoid arthritis compared with placebo or adalimumab with MTX up to 48 weeks of follow-up.

Read more

Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL* protocol

Teodoro Iturbe-Hernandez MD, Luis García de Guadiana Romualdo MD, Ignacio Gil Ortega MD, Antonio Martínez Francés MD, Olga Meca Birlanga MD, Juan José Cerezo-Manchado MD

Article Type

Original Research

Published

In this review, the available information on the antithrombotic management of atrial fibrillation patients at discharge after COVID-19 infection is updated. In addition, a practical algorithm, considering renal and liver function, which facilitates the anticoagulation choice at discharge is presented.

Read more

Bempedoic acid for the treatment of dyslipidemia

Joel C Marrs PharmD, MPH, Sarah L Anderson PharmD

Article Type

Review

Published

This narrative review aims to present and discuss the current evidence regarding the use of bempedoic acid for low-density lipoprotein-cholesterol lowering in patients with dyslipidemia and its potential role as an agent to lower cardiovascular events.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.